Nektar Therapeutics (NKTR)
1.17
-0.05
(-4.10%)
USD |
NASDAQ |
Jul 02, 16:00
1.17
0.00 (0.00%)
After-Hours: 17:10
Nektar Therapeutics Research and Development Expense (TTM): 111.10M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 111.10M |
| December 31, 2023 | 114.16M |
| September 30, 2023 | 118.96M |
| June 30, 2023 | 128.48M |
| March 31, 2023 | 141.54M |
| December 31, 2022 | 218.32M |
| September 30, 2022 | 283.20M |
| June 30, 2022 | 353.34M |
| March 31, 2022 | 411.92M |
| December 31, 2021 | 400.27M |
| September 30, 2021 | 403.38M |
| June 30, 2021 | 400.17M |
| March 31, 2021 | 395.30M |
| December 31, 2020 | 408.68M |
| September 30, 2020 | 416.32M |
| June 30, 2020 | 414.84M |
| March 31, 2020 | 425.09M |
| December 31, 2019 | 434.57M |
| September 30, 2019 | 433.08M |
| June 30, 2019 | 436.93M |
| March 31, 2019 | 418.58M |
| December 31, 2018 | 399.54M |
| September 30, 2018 | 372.08M |
| June 30, 2018 | 334.90M |
| March 31, 2018 | 306.83M |
| Date | Value |
|---|---|
| December 31, 2017 | 268.46M |
| September 30, 2017 | 237.26M |
| June 30, 2017 | 223.50M |
| March 31, 2017 | 215.59M |
| December 31, 2016 | 203.80M |
| September 30, 2016 | 200.70M |
| June 30, 2016 | 191.98M |
| March 31, 2016 | 185.04M |
| December 31, 2015 | 182.79M |
| September 30, 2015 | 174.15M |
| June 30, 2015 | 165.12M |
| March 31, 2015 | 156.41M |
| December 31, 2014 | 147.73M |
| September 30, 2014 | 157.49M |
| June 30, 2014 | 167.20M |
| March 31, 2014 | 182.73M |
| December 31, 2013 | 190.01M |
| September 30, 2013 | 188.14M |
| June 30, 2013 | 178.24M |
| March 31, 2013 | 159.21M |
| December 31, 2012 | 148.68M |
| September 30, 2012 | 135.60M |
| June 30, 2012 | 132.61M |
| March 31, 2012 | 131.68M |
| December 31, 2011 | 126.77M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
111.10M
Minimum
Mar 2024
434.57M
Maximum
Dec 2019
316.46M
Average
400.17M
Median
Jun 2021
Research and Development Expense (TTM) Benchmarks
| Assertio Holdings Inc | 3.576M |
| Ligand Pharmaceuticals Inc | 23.84M |
| Verastem Inc | 67.05M |
| Cara Therapeutics Inc | 106.14M |
| Ocugen Inc | 36.84M |